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The different pharmacologic properties of plants-containing cynaropicrin, especially
artichokes, have been known for many centuries. More recently, cynaropicrin exhibited
a potential activity against all genotypes of hepatitis C virus (HCV). Cynaropicrin has also
shown a wide range of other pharmacologic properties such as anti-hyperlipidemic,
anti-trypanosomal, anti-malarial, antifeedant, antispasmodic, anti-photoaging, and
anti-tumor action, as well as activation of bitter sensory receptors, and anti-inflammatory
properties (e.g., associated with the suppression of the key pro-inflammatory NF-κB
pathway). These pharmacological effects are very supportive factors to its outstanding
activity against HCV. Structurally, cynaropicrin might be considered as a potential drug
candidate, since it has no violations for the rule of five and its water-solubility could allow
formulation as therapeutic injections. Moreover, cynaropicrin is a small molecule that can
be easily synthesized and as the major constituent of the edible plant artichoke, which
has a history of safe dietary use. In summary, cynaropicrin is a promising bioactive natural
product that, with minor hit-to-lead optimization, might be developed as a drug for HCV.
Keywords: cynaropicrin, anti-hepatitis C virus, anti-hyperlipidemic, antitumor, anti-inflammatory, anti-parasite,
antibacterial, anti-gastritis action
INTRODUCTION
Cynaropicrin (Figure 1) is a sesquiterpene lactone of a guaianolide type. It has a 5-7-5 fused tricyclic
skeleton with six stereocenters, four exo-olefins, and two hydroxyl groups. The γ-butyrolactone
ring is a very important pharmacophore which is implicated in many biological activities of
cynaropicrin. In 1960, cynaropicrin was first isolated from artichoke (Cynara scolymus L.) (Suchy
et al., 1960) and it is now considered as a chemotaxonomic marker of artichoke plants (Chaturvedi,
2011). The artichoke plants are known to exhibit significant pharmacological effects and health
benefits that have recently been reviewed (Ben Salem et al., 2015).
The bitter taste of artichoke plants is attributed to its high content of sesquiterpene lactones,
especially of cynaropicrin. Cynaropicrin contributes to approximately 80% of the characteristic
bitter taste of artichoke, which is associated with the activation of bitter sensory receptors (Cravotto
et al., 2005; Eljounaidi et al., 2015). Cynaropicrin can be isolated in gram-scale by employing
countercurrent chromatography (Adekenova et al., 2015). 1H NMR spectroscopy and titration
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FIGURE 1 | Structure of cynaropicrin.
of the lactone ring with sodium hydroxide were used for
the quantitative determination of cynaropicrin (Schneider and
Thiele, 1974a,b; Pieri and Stuppner, 2011).
The chemical resonance peaks in the 13C NMR of many
sesquiterpene lactones including cynaropicrin and some of its
derivatives were reported (Budesinsky and Saman, 1995). The
hydroxy pentanoid ring is cis fused to the heptanoid ring and the
lactone ring has a transoid orientation with the heptanoid one.
The absolute stereochemistry of cynaropicrin was determined by
chemical relation to α-santonin (Corbella et al., 1972).
Cynaropicrin is a sesquiterpene lactone; sesquiterpene
lactones are the most biologically significant class of secondary
metabolites. Cynaropicrin has been shown to possess various
biological activities and has demonstrated extraordinary
pharmacologic properties such as anti-hepatitis C virus,
anti-parasitic, anti-tumor, anti-hyperlipidemic, antifeedant,
antispasmodic, anti-photoaging agent, activation of bitter
sensory receptors, suppression of NF-κB, and anti-inflammatory
properties.
ANTI-HEPATITIS C VIRUS (ANTI-HCV)
ACTIVITY
Human infection with HCV is currently recognized as the
leading cause of chronic liver diseases such as hepatic steatosis,
liver cirrhosis, and hepatocellular carcinoma (HCC), which
demands liver transplantation (Ishida et al., 2014). Hepatitis
C virus infection is a significant public health problem with
approximately 200 million people around the world being
infected with HCV (Tsantrizos, 2008; Ibrahim et al., 2013).
About 3–4 million people are infected per year, and the
World Health Organization (WHO) reported that approximately
700,000 people die each year from hepatitis C-related liver
diseases (http://www.who.int/mediacentre/factsheets/fs164/en/),
with the US mortality rates from HCV now exceeding those
from HIV. The overall medical and social costs of chronic HCV
infections are estimated to exceed $85 billion (Ibrahim et al.,
2013).
The wild Egyptian artichoke exhibited promising activity
against HCV (Elsebai et al., 2016a) which were related to its
sesquiterpene lactones especially cynaropicrin (Elsebai et al.,
2016b). Cynaropicrin demonstrated outstanding activity against
HCV since, for the first time, the performed in vitro studies
showed that cynaropicrin has potent and broad spectrum activity
as a cell-entry inhibitor against all genotypes of HCV with
EC50 in the low micromolar range (Elsebai et al., 2016b).
Cynaropicrin acts during the early steps of the HCV lifecycle,
including cell-free and cell-cell infection inhibition. HCV is
transmitted between hepatocytes via classical cell entry using
cell-free diffusion but also uses direct cell-cell transfer to infect
neighboring cells. Interestingly, cynaropicrin efficiently inhibited
cell-cell transmission, which was confirmed by using a co-culture
of two different cell types: Huh7/Scr cells infected with the
Jc1 virus act as HCV donor cells while Huh7.5/EGFP-NLS-IPS
cells act as acceptor cells. Furthermore, the antiviral activity
of cynaropicrin was pan-genotypic as HCV genotypes 1a, 1b,
2b, 3a, 4a, 5a, 6a, and 7a were inhibited. Thus, cynaropicrin
is a promising candidate for the development of new and
cost-effective pan-genotypic entry inhibitors of HCV infection
(Elsebai et al., 2016b). The following pharmacological effects can
be linked directly or indirectly with the promising anti-HCV
activity of cynaropicrin. Overview of reported pharmacological
effects of cynaropicrin is presented on Figure 2.
ANTI-HYPERLIPIDEMIC ACTIVITY
The leaf-extract of artichoke (Cynara scolymus L.) suppressed
serum triglyceride elevation in olive oil-loaded mice. This anti-
hyperlipidemic activity might be through the suppression of
gastric emptying. Cyanopicrin, aguerin B, and grosheimin were
isolated as the anti-hyperlipidemic compounds and the activity
of cynaropicrin was the most potent among them. The oxygen
functional groups and exo-methylene moiety in α-methylene-γ-
butyrolactone ring were essential for the activity of these guaiane-
type sesquiterpenes (Shimoda et al., 2003). A set of tricyclic
sesquiterpene lactones including cynaropicrin was applied for
patenting in the treatment of obesity and related diseases and
non-therapeutic treatable conditions (Grothe et al., 2013).
ANTI-TUMOR AND CYTOTOXIC ACTIVITY
Cho et al. reported that the cynaropicrin is the first naturally
occurring compound which modulates the functional activation
of major adhesion molecules (CD29 and CD98) in macrophages,
using a quantitative aggregation assay established with U937
cells and activating antibodies to their major adhesion
molecules (Cho et al., 2004a). The activation of adhesion
molecules is an essential factor in regulating inflammatory
process. Once activated, immune cells migrate to inflamed
tissues and cell-cell adhesion is facilitated (Muller, 2003).
Cynaropicrin inhibited CD98- and CD29 (β1 integrins)-
induced homotypic aggregation with IC50 values of 2.98 and
3.46 µM, respectively, without displaying cytotoxicity. On
the contrary, CD43-induced hemolytic aggregation was not
inhibited, suggesting that cynaropicrin-induced inhibition is
due to a specific immunopharmacological effect. In addition,
cynaropicrin regulatory effect on CD29 and CD98 is mediated
through the inhibition of extracellular signal-related kinase
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FIGURE 2 | Pharmacological effects of cynaropicrin.
(ERK) pathway. Cynaropicrin is considered as a potential
drug for treatment of CD29- and CD98-mediated diseases
such as virus-induced chronic inflammation, and invasion,
migration, and metastasis of leukocyte cancer cells (Cho et al.,
2004a).
Cynaropicrin may be a potential anticancer agent against
some leukocyte cancer cells such as lymphoma or leukemia,
through pro-apoptotic activity. The cytotoxic effect of
cynaropicrin against macrophage, eosinophil, fibroblast,
and lymphocyte cell lines was evaluated. Cynaropicrin showed
selective potential antiproliferative activity against differentiated
human macrophage (U937 cells), Eol-1 and Jurkat T leukocyte
cell lines. Meanwhile, it was not as active against Chang liver
cells and human fibroblast cell lines. The mechanism of the
cytotoxic effect of cynaropicrin on U937 cells was found to be
mediated through induction of apoptosis and cell cycle arrest
at G1/S phase. Cynaropicrin cytotoxic activity was inhibited in
presence of N-acetyl-L-cysteine and L-cysteine, reactive oxygen
species (ROS) scavengers, or rottlerin [protein kinase (PK) Cδ
inhibitor]. Therefore, it was concluded that PKCδ and ROS are
important for the pro-apoptotic activity of cynaropicrin due to
the cynaropicrin-induced proteolytic cleavage of PKCδ (Cho
et al., 2004b).
The ethanol extract of the aerial part of the Mongolian
medicinal plant Saussurea salicifolia induced a dose-dependent
cell growth inhibition in both human gastric adenocarcinoma
(AGS) cells and mouse hepatoma Hepa 1c1c7 cells (IC50 = 30.22
and 116.96 µg/ml, respectively). Seven bioactive compounds
causing the apoptosis were isolated including cynaropicrin, three
lignans (arctigenin, matairesinol, and trachelogenin) and three
lignan glycosides (arctiin, matairesinoside, and tracheloside).
Cynaropicrin and arctigenin were the most active and they
inhibited the proliferation and induced apoptosis in AGS
cells (IC50 = 0.68 and 31.90 µg/ml, respectively) in a dose-
dependent manner. Thus, cynaropicrin and arctigenin are
thought to be responsible for the antiproliferative and pro-
apoptotic activity of S. salicifolia total extract in AGS cells.
Therefore, cynaropicrin may serve as a potential drug lead
for treatment or prevention of human cancers (Kang et al.,
2007).
Cynaropicrin suppressed IL-6-inducible and constitutive
Signal Transducer and Activator of Transcription 3 (STAT3)
activation (Butturini et al., 2013). STAT3 is a cytoplasmic
transcription protein factor that is activated in various cancers.
STAT3 is controlled not only by phosphorylation but also by S-
glutathionylation. It inhibits apoptosis, induces chemoresistance,
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stimulates cell proliferation, and promotes angiogenesis,
invasion, and migration. Consequently, STAT3 is considered as
a potential cancer therapeutic target through counteracting its
hyper-expression or hyper-activation. In the human prostate
cancer cell line DU145, that constitutively express active STAT3,
STAT3 inhibition led to the suppression of two anti-apoptotic
genes, Bcl-2 and denocarc. With an IC50 of 12 µM, cynaropicrin
inhibited both IL-6-inducible and constitutive STAT3 activation
in THP- 1 cells and the cell line DU145. It showed synergistic
effects with the chemotherapeutic agents cisplatin or docetaxel.
Cynaropicrin induces a rapid drop in intracellular GSH
concentration in a dose-dependent manner through Michael
addition reaction, thereby triggering S-glutathionylation of
STAT3, interfering with its phosphorylation. Cynaropicrin was
found to regulate STAT3 function through induction of redox-
dependent post-translational modification of STAT3 cysteine
residues (Butturini et al., 2013).
Multiple cancer drugs established in clinics act via exhibiting
genotoxic effects targeting proliferating cancer cells (Swift and
Golsteyn, 2014). The genotoxic potential of cynaropicrin was
evaluated using the Homozygotization Index (HI) test on
two diploid strains of Aspergillus nidulans: UT184//UT448,
with normal DNA repair mechanisms; and Dp II-I//UT184,
presenting recombinational repair mechanisms only. Potential
genotoxic/ carcinogenic compounds can be detected by this test
at low doses. Treatments of UT448/UT184 and Dp II-I/UT184
diploid strains with cynaropicrin at a concentration of 25 µg/ml
increased the HI of both strains, especially for the diploid
Dp II-I/UT184. This is the first time the low dose effect of a
bioactive natural product such as cynaropicrin was detected using
A. nidulans (Salvador et al., 2008).
Cynaropicrin and desacylcynaropricrin (isolated from the
Tibetan plant Saussurea eopygmaea, Compositae) have in vitro
activity against both solid and ascites tumors (S-180 sarcoma
and Ehrlich carcinoma) with IC50 values of 2.5 and 2.4 µg/ml
for cynaropicrin and 1.5 and 1 µg/ml for desacylcynaropricrin,
respectively (Zong et al., 1994). Cynaropicrin (from the flowers of
Hemisteptia lyrata Bunge) showed cytotoxic activity against SK-
OV-3 (human ovary adenocarcinoma cell), LOX-IMVI (human
melanoma cell), A549 (human non-small lung adenocarcinoma
cell), MCF-7 (human breast adenocarcinoma cell), PC-3 (human
prostate adenocarcinoma cell), and HCT-15 (human colorectal
adenocarcinoma cell) cell lines with IC50 values between 1.1 and
8.7 µg/ml (Ha et al., 2003). Cynaropicrin (from the aerial parts
of Centaurothamnus maximus, Compositae) showed in vitro
cytotoxic activity against human cancer cell lines of malignant
melanoma (SK-MEL), as well as against epidermoid (KB), ductal
(BT-549) and SK-OV-3 carcinomas with IC50 values between
2.0 and 6.3 µg/ml (Muhammad et al., 2003). The cytotoxicity
of cynaropicrin (from Saussurea calcicola, Compositae) was
examined using a Sulforhodamin B Bioassay (SRB) against
the five cultured human tumor cells: A549, SK-OV-3, SK-
MEL-2, XF498 (CNS), and HCT-15. Cynaropicrin showed non-
specific significant cytotoxicity against those human tumor
cell lines with ED50 values ranging from 0.29 to 1.37µg/ml
(Choi et al., 2005). In another study, cynaropicrin (from the
aerial parts of Saussurea pulchella, Asteraceae) exhibited a
promising cytotoxicity against SK-MEL-2 and SK-OV-3 human
tumor cell lines with ED50 values of 4.07 µM, and 7.42 µM,
respectively. It showed also weak cytotoxicity against A549 and
HCT (colon adenocarcinoma) with ED50 values of 24.51 and
12.13 µM, respectively. Doxorubicin was used as a positive
control and its cytotoxicity against A549, SK-OV-3, SK-MEL-
2, and HCT cell lines were ED50 0.007, 0.056, 0.117, and 0.164
µM, respectively (Yang et al., 2008). Furthermore, cynaropicrin
(from the aerial parts of Centaurea omphalotricha, Asteraceae)
and cynaropicrin derivatives (3-acetyl cynaropicrin and 4′-acetyl
cynaropicrin) were found to be cytotoxic compounds against
human leukemia cell lines HL-60 and U937 with IC50 values
of 2.0 ± 0.9 and 5.1 ± 0.4 µM, respectively (Kolli et al.,
2012).
Although cynaropicrin, being the major constituent of the
edible plant artichoke, has a history of safe dietary use in
humans, toxic effects were studied in some animal species.
Ingestion of yellow star thistle (Centaurea solstitialis) by horses,
but not cattle or sheep, produces Parkinsonism due to nigro-
pallidal degeneration. The “chewing disease” or “yellow star
thistle poisoning,” occurred in 1954 in central and northern
California, was experimentally linked to the ingestion of large
amounts of C. solstitialis. Thistle poisoning develops in horses
within 1–3 months of feeding on the mentioned plant. It is
characterized by facial muscle immobility, chewing problems and
flicking of the tongue. This leads to inability to eat or drink
normally, followed by hypokinesia and a lack of reactivity and
eventually death. The dichloromethane extract of C. solstitialis
was neurotoxic to neuronal cultures of fetal rat brain. Upon
bioguided fractionation of the extract, 13-O-acetylsolstitialin A
(Figure 3) and cynaropicrin exhibited neurotoxic activity in the
test system using ratmesencephalic full culture where they caused
a concentration-dependent reduction in the percentage of living
cells with IC50 values of 3.6 and 3.0µM, respectively (Wang et al.,
1991; Cheng et al., 1992).
Applied on rabbit isolated aortic ring preparations,
cynaropicrin was shown to induce toxic inhibition of
smooth muscle contractility. The chemically-reactive α-
methylenebutyrolactone function group is the pharmacophore
moiety of the compound and is an essential functionality for
smooth muscle inhibitory activity (Hay et al., 1994).
FIGURE 3 | Structure of 13-O-acetylsolstitialin A.
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ANTI-INFLAMMATORY ACTIVITY
TNF-α is a cytokine produced by many cells, especially
lymphocytes andmacrophages, which has an essential role in host
chronic and acute inflammatory reactions. During inflammation,
these cells are proliferated and activated by inflammatory
signals (e.g., bacterial products such as lipopolysaccharide,
concanavalin A, or phytohemagglutinin). Accordingly,
different pro-inflammatory mediators are produced, such
as cytokines (TNF-α, IL-1 and -6), eicosanoids (leukotriene B4
and prostaglandin E2), as well as reactive oxygen and nitrogen
intermediates including nitric oxide (Cho et al., 2000). TNF-α
is a monocyte-derived cytotoxin and cytokine that triggers the
inflammatory reaction and hence its production deregulation is
associated with autoimmune complications of human diseases
such as rheumatoid arthritis, psoriasis, Alzheimer’s disease,
refractory asthma, cancer, and inflammatory bowel disease
(IBD). It is implicated in tumorigenesis inhibition (TNF-α causes
cytolysis of certain tumor cell lines) and viral replication and
response to sepsis via IL1 & IL6 producing cells (Kriegler et al.,
1988).
Cynaropicrin has potent suppressive effects on TNF-α
and cytokine-induced neutrophil chemoattractant-1 and
nitric oxide release, suggesting that cynaropicrin may be a
useful agent toward acute and chronic inflammatory diseases.
Cynaropicrin (from Saussurea lappa) strongly inhibited,
at non-cytotoxic concentrations, the production of TNF-
α from lipopolysaccharide-stimulated murine macrophage
RAW264.7 cells, and U937 cells which are known producers
of TNF-α (Cho et al., 1998). In a dose-dependent manner,
cynaropicrin also potently inhibited the release of nitric
oxide from lipopolysaccharide- and interferon-γ-stimulated
RAW264.7 cells. Also in a dose-dependent manner, cynaropicrin
suppressed lymphocytes proliferation from splenocytes and
IL-2-sensitive cytotoxic T lymphocytes, CTLL-2 cells, stimulated
by lipopolysaccharide, phytohemagglutinin, concanavalin A,
and IL-2. Treatment with sulfhydryl (SH) compounds such as
L-cysteine, 2-mercaptoethanol, and dithiothreitol abrogated all
these inhibitory effects of cynaropicrin on TNF-α production
and hence it was concluded that cynaropicrin may participate
in the inflammatory response by inhibiting the production of
inflammatory mediators and the proliferation of lymphocytes
(Cho et al., 2000).
ANTIPHOTOAGING AND ANTIOXIDANT
ACTIVITIES
Photoaging is the main causative agent for the increased risk for
skin cancer and the appearance of damaged skin. Aging of the
skin is a complicated biological process, which is characterized by
skin wrinkling, laxity, and pigmentation, and induced by several
environmental and biological factors. The most common factor
is the ultraviolet irradiation; the burning rays UVB (280–320 nm)
makes up ∼5% of UV light and UVB causes sunburn 1000 times
more than UVA and is responsible for the photo-induced skin
damage. UVB irradiation induces several intracellular signaling
pathways leading eventually to the formation of ROS. The later, in
turn, leads to the damage of vital macromolecules such as lipids,
proteins, and nucleic acids in keratinocytes. Eventually, this will
contribute to the process of photocarcinogenesis and photoaging.
In addition, UVB irradiation induces the release of various pro-
inflammatory cytokines in keratinocytes such as IL-6 and TNF-α
which finally activate NF-κB (Fisher et al., 2002).Many researches
showed that excessive activation of NF-κB has an essential role for
skin photoaging and other disorders such as cancer, psoriasis, and
rheumatism. NF-κB stimulation will increase the production of
matrix metalloprotease-1 (MMP-1) and basic fibroblast growth
factor (bFGF) which causes epidermal thickening, due to
hyperproliferation, and pigment deposition, due to melanocyte
proliferation, leading finally to photoaging. The UVB-induced
skin photoaging processes are ascribable to the activation of NF-
κB, which exist in epidermal keratinocyte and dermal fibroblasts
(Balistreri et al., 2013). Therefore, NF-κB inhibitors will be novel
ingredients in the anti-aging skin care treatments. Cynaropicrin
is a very effective antiphotoaging agent acting by suppression
of the NF-κB-mediated transactivation of bFGF and MMP-1
without significant cytotoxicity. Cynaropicrin prevented skin
photoaging processes in an in vivo mouse model experiments
(Tanaka et al., 2013).
Cynaropicrin is a very potent activator for AhR (aryl
hydrocarbon receptor)–Nrf2 (nuclear factor E2–related factor
2)–Nqo1 (NAD(P)H:quinone oxidoreductase 1) pathways
in normal human keratinocytes. In addition, it decreases the
generation of ROS and the production of inflammatory cytokines
in UVB-irradiated keratinocytes. Therefore, cynaropicrin
could be applied to prevent UVB-induced photoaging. The
cynaropicrin-induced AhR–Nrf2–Nqo1 activation was AhR-
and Nrf2-dependent [Nrf2 is a key transcription factor
that upregulates a series of antioxidative enzymes such as
NAD(P)H:quinone oxidoreductase 1 (Nqo1)], as observed from
that it was absent in keratinocytes transfected by siRNA (small
interfering RNAs) against either AhR or Nrf2. In parallel with the
activation of the AhR–Nrf2–Nqo1 system, cynaropicrin actively
inhibited generation of ROS from keratinocytes irradiated with
UVB in a Nrf2-dependent manner. Nqo1 is one of the key
antioxidant enzymes that efficiently inhibit ROS production in
keratinocytes. Cynaropicrin is a potent antioxidant since its EC50
and CC50 on Nqo1 induction was 0.89 ± 0.14 and 47.6 ± 2.8
µM, respectively, in keratinocytes. Cynaropicrin also inhibited
the production of pro-inflammatory cytokines such as IL-6 and
TNF-α from UVB-treated keratinocytes (Takei et al., 2015).
In a placebo-controlled study with 8 volunteers, the artichoke
leaf extract (contains 0.7% cynaropicrin) improved the facial
pigmentation, conspicuous pores, and wrinkles after 8 weeks of
intake through preventing the decline of dermal proteoglycan,
which is important for water holding function (Takahashi,
2014).
The effect of cynaropicrin on the wasting syndrome
(cachexia) and oxidative stress elicited by 2,3,4,7,8-
pentachlorodibenzofuran (PenCDF) was evaluated in mice.
Cynaropicrin has an ability to reduce oxidative stress caused
by PenCDF by studying its effect on PenCDF-induced toxicity
in C57BL/6J mice, a responsive strain to dioxins. Since
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2,3,7,8-tetrachlorodibenzo-p-dioxin (0.1mg/kg) induces hepatic
ethoxyresorfin O-deethylase (EROD) activity in mice, however,
this compound up to 20mg/kg (p.o.) did not attenuate PenCDF-
induced cachexia. On the contrary, PenCDF-induced oxidative
stress was suppressed by cynaropicrin at the highest dose
(20mg/kg), although EROD activity was increased rather
than reduced by cynaropicrin at lower doses (Yamada et al.,
2015).
ANTIBACTERIAL ACTIVITY
Cynaropicrin is a potent, irreversible inhibitor of the bacterial
enzymeMurAwhich is of vital importance for bacterial cells since
this enzyme is responsible for the first step in the cytoplasmic
biosynthesis of peptidoglycan precursor molecules. Cynaropicrin
covalently binds to the thiol group of Cys115 through Michael
addition reaction. Bachelier et al. presented the first explanation
of the antibacterial mode of action of sesquiterpene lactones
on a molecular basis using Escherichia coli. Judging from the
structure-activity relationships with other studied sesquiterpene
lactones, the unsaturated ester side chain of cynaropicrin is of
particular importance for the inhibition ofMurA. In contrast, the
α-methylene-γ-butyrolactone group and the exocyclic methylene
moiety in the macrocyclic part of the cynaropicrin are less
relevant. Concerning the binding mode, the ester side chain of
cynaropicrin mimic the substrate phosphoenolpyruvate (PEP),
whereas the macrocyclic part of the molecule is of minor
importance (Bachelier et al., 2006).
ANTI-PARASITIC ACTIVITY
The human parasite infections include deadly protozoal diseases,
especially in tropical and subtropical developing countries.
Human African trypanosomiasis (HAT) or sleeping sickness
is caused by the protozoan parasite Trypanosoma brucei and
is transmitted by blood-feeding tsetse flies (Glossina spp.
Wiedemann) occurring in sub-Saharan Africa. The disease is fatal
when left untreated. Currently, there are about 30,000 new HAT
cases annually, and as many as 30 million people live in HAT
endemic areas. In Central and Western Africa, about 95% of
HAT cases are caused by T. b. gambiense, which causes a chronic
form of sleeping sickness that can extend for months or years
before the appearance of clinical symptoms. T. b. rhodesiense
is endemic to Eastern Africa and causes the other 5% of cases
and its infection causes an acute, more virulent form of HAT.
A nonspecific malaise syndrome (the first stage) manifests both
HAT forms, followed by the invasion of the parasites into the
central nervous system (CNS) (the encephalitic stage) which
triggers the progressive breakdown of neurological functions,
including the disruption of the sleep cycle. Both HAT forms are
life-threatening if not treated adequately (Zimmermann et al.,
2012, 2014).
Cynaropicrin is the first plant-derived natural product with
in vivo activity against T. brucei. It has reduced parasitemia
in the murine model of trypanosomiasis and also it has
potent antitrypanosomal activity in vitro (Zimmermann et al.,
2012). Cynaropicrin (from the herb Centaurea salmantica L.,
Asteraceae) showed an in vitro inhibition of T. brucei rhodesiense.
It causes a significant inhibition against T. b. rhodesiense
and T. b. gambiense with IC50 values of 0.3 and 0.2 µM,
respectively. However, it has a relatively moderate activity against
Trypanosoma cruzi and Plasmodium falciparum with IC50 values
of 4.4 and 3.0 µM, respectively. On day seven post-infection,
I.p. administration of 2 × 10mg/kg body wt/day in the T. b.
rhodesiense STIB 900 acute mouse model (this model mimics the
first stage of the HAT) resulted in a 92% reduction of parasitemia
compared to untreated controls (Zimmermann et al., 2012; da
Silva et al., 2013).
The antitrypanosomal activity of cynaropicrin is mediated
by the depletion of intracellular glutathione (GSH) and
trypanothione (T(SH)2) (which the trypanosomes depend on
for redox regulation) as well as the inhibition of trypanosomal
ornithine decarboxylase. This action was mediated by the
cynaropicrin α,β-unsaturated methylene moiety which
acts as Michael acceptor for (GSH) and trypanothione
(T(SH)2). The analysis of this mechanism and the effects
of cynaropicrin on enzymes of the T(SH)2 redox metabolism
including glutathione-S-transferase, trypanothione synthetase,
trypanothione reductase, and ornithine decarboxylase were
established with UPLC–MS/MS analysis and the intra-cellular
cynaropicrin, T(SH)2, GSH, as well as GS-cynaropicrin and
T(S-cynaropicrin)2 adducts in intact T. b. rhodesiense cells were
quantified. The cellular GSH and T(SH)2 pools were entirely
depleted, within minutes of exposure to cynaropicrin, and the
parasites entered an apoptotic stage and died. Cynaropicrin
also inhibited the ornithine decarboxylase likewise the positive
control eflornithine (Zimmermann et al., 2013).
The in vitro structure–activity-relationship (SAR) study
of synthetic cynaropicrin derivatives against T. brucei was
described. The side chain moiety of cynaropicrin plays a
crucial role in its inhibitory activity. Removal of the 2-
hydroxymethyl-2-propenoyl moiety of cynaropicrin (producing
deacylcynaropicrin, Figure 4) resulted in a loss of toxicity toward
T. b. rhodesiense and exhibited activity against T. brucei ten times
less than that of cynaropicrin (Zimmermann et al., 2012).
Further derivatives were synthesized exploiting the hydroxyl
groups in cynaropicrin and all of these compounds were
tested for in vitro activity against T. b. rhodesiense. Based
on the results of the SAR study, Usuki et al. concluded the
following: “(1) an acyl side chain at OH-8 is essential for
antitrypanosomal activity and the 2-hydroxylmethyl-2-propenoic
acid side chain affects SI value; (2) changing the hydrophilicity
of the OH-3 substituent affects neither antitrypanosomal activity
nor cytotoxicity; (3) changing the hydrophilicity of OH-19
group does not affect the antitrypanosomal activity, but does
influence the cytotoxicity; (4) formation of an ester at the OH-
19 position decreases both the antitrypanosomal activity and
cytotoxicity; and (5) introduction of Ac groups at OH-19 and
OH-3 positions leads to a decrease in both the antitrypanosomal
activity and cytotoxicity” (Usuki et al., 2014). These results
suggest that derivatization of the two hydroxyl groups in
cynaropicrin does not significantly affect the antitrypanosomal
activity (Usuki et al., 2014). Additionally, many semi-synthetic
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FIGURE 4 | Structures of deacylcynaropicrin and dimethylamino cynaropicrin derivative.
sesquiterpene lactones and amino-sesquiterpene lactones were
in vitro tested against T. b. rhodesiense and mammalian
cancer cells (rat bone myoblast L6 cells). It was found
that the α-methylene-γ-lactone moiety is necessary for both
antitrypanosomal effects and cytotoxicity. Antitrypanosomal
selectivity is facilitated by 2-(hydroxymethyl)acrylate (as in
cynaropicrin) or 3,4-dihydroxy-2-methylenebutylate side chains,
and by the presence of cyclopentenone rings. Semi-synthetic
amino-cynaropicrin with dimethylamino group (Figure 4) was
tested in the T. b. rhodesiense acute mouse model, where
it showed reduced toxicity over cynaropicrin, but also lost
antitrypanosomal activity (Zimmermann et al., 2014).
The trypanocidal activity of cynaropicrin was also evaluated
against Trypanosoma cruzi (the causative agent of Chagas disease
= American trypanosomiasis). The in vitro studies done by
Schinor et al. showed that cynaropicrin (isolated from the
Brazilian plant Moquinia kingii, Asteraceae) has an IC50 value
of 93.5 µg/ml (Schinor et al., 2004). The in vitro studies done
by Da Silva et al. showed that although cynaropicrin presented
quite considerable trypanocidal effects in vitro (as effective as the
control drug benznidazole), the treatment (once or twice a day)
of T. cruzi-infected mice (up to 50mg/kg/day) did not suppress
parasitemia or protect against mortality induced by the Y and
Colombiana strains compared to benznidazole (da Silva et al.,
2013). In another study, the in vitro activity of cynaropicrin (from
Vernonia mespilifolia, Asteraceae) against Trypanosoma brucei
rhodesiense, T. cruzi, Leishmania donovani, and P. falciparum
showed promising findings with IC50 values of 0.23, 5.14, 1.56,
and 1.56 µM, respectively (Mokoka et al., 2011, 2013).
Cynaropicrin [from Saussurea salsa (Pall.) Spreng.] showed
promising antiopisthorchiatic activity which has been studied
in vivo on a model of opisthorchiasis in golden hamsters.
Cynaropicrin produced a dose-dependent therapeutic effect
comparable with that of the reference antischistosomal drug
praziquantel (Drab et al., 2005).
ANTIFEEDANT ACTIVITY
Cynaropicrin is a promising antifeedant compound, which
deserves further attention for development as an ecologically
safe plant product for insect control and deterrent against
herbivory. Cynaropicrin (from Centaurea ptosimopappa Hayek
and Trichlorepis glaberrima DC, Compositae) showed a potent
feeding deterrent activity against several species of Lepidoptera.
Cynaropicrin proved to be a potent antifeedant on testing against
4th instar larvae of Bihar hairy caterpillar, Diacrisia obliqua
Walker (Lepidoptera: Arctiidae) and the Erisilk worm Philosamia
riciniHutton (Lepidoptera: Saturniidae). The compound retained
appreciable feeding deterrence up to two days from treatment
(Bhattacharyya et al., 1995). Cynaropicrin (from aerial parts of
Rhaponticum pulchrum) showed medium antifeedant activities
(with an average index value activity of 66.6) against three species
of stored product insect pests of Sitophilus granarius beetles,
Tribolium confusum larvae and Trogoderma granarium larvae in
no-choice and 2-choice feeding experiments (Cis et al., 2006).
GASTRIC ACTIONS
Cynaropicrin possesses a marked effect on mucosal injuries,
preventing acute gastritis. Using acute gastric mucosal injury
in rats, the artichoke leaf extract exhibited an anti-gastritis
action (gastric cytoprotective activity) which was attributed
to its content of cynaropicrin, at least in part, by its
gastric mucus glycoprotein-increasing action. Additionally,
cynaropicrin increased the volume of gastric juice by stimulating
the secretion of saliva and gastric juice secretion due to its bitter
stomachic character (Ishida et al., 2010). Cynaropicrin is one
of the main active choleretic ingredients in Saussurea amara
where cynaropicrin at low and intermediate concentrations
provoked a dose-dependent increase in bile flow in the perforated
rat liver perfusion system which was even more than cynarin
and apigenin-7-O-glucoside. Higher doses of pure cynaropicrin
(20mg/L) caused liver damage (Glasl et al., 2007). Overall, the
beneficial gastric actions of moderate amounts of cynaropicrin
that are present in artichoke leaf extracts may be the reason
behind their massive and global use to ameliorate dyspeptic
symptoms (Marakis et al., 2002).
Cynaropicrin (from the Brazilian Cynara scolymus) is a
promising antispasmodic agent since it showed potent inhibitory
effect on the contractile response elicited by acetylcholine
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on guinea-pig ileum in a noncompetitive and concentration-
dependent manner, with an IC50 value of 0.065mg/ml and having
similar potency to that of papaverine. Cynaropicrin did not show
any agonist effect, as it did not interfere with the basal tension
of the preparations. In addition, after successive washings, the
contractile response to agonists was restored. These findings are
consistent with the popular use of artichoke as a home remedy for
the treatment of gastrointestinal disturbances (Emendörfer et al.,
2005). In the same context, another recent study showed that
cynaropicrin has a weak in vitro acetyl cholinesterase inhibition
with an IC50 value of 10 µg/ml and radical scavenging activity
against 1,1-diphenyl-2-picryl-hydrazil (DPPH) radicals (Hegazy
et al., 2016).
The different discussed activities of cynaropicrin including the
model, dose and its source are summarized in Table 1.
BIOSYNTHESIS
The highest concentration of cynaropicrin is found in leaves
(9.6± 0.4mg.g−1 DW), regardless of their stage of development,
suggesting they are likely the place where cynaropicrin is
synthetized and stored; cynaropicrin predominantly accumulates
in the trichomes. Other plant organs such as the receptacle show
a progressively decreasing content of cynaropicrin during the
inflorescence development. At the same time, for stems, roots and
bracts, cynaropicrin was undetectable (Eljounaidi et al., 2015).
Cynaropicrin is formed from three isoprene C5 units and
synthesized via mevalonate pathway. Cynaropicrin is likely
derived from the common precursor costunolide, the product of
germacrene A, by the action of two cytochrome P450 enzymes
(Cytochrome P450s from C. cardunculus CYP71BL5 and
CYP71AV9, catalyze specific hydroxylations in the sesquiterpene
lactone biosynthetic pathway). Therefore, germacrene A
biosynthesis is assumed to be the first committed step in the
biosynthesis of cynaropicrin and generally for guaianolide
sesquiterpene lactones (Figure 5). Cyclization of farnesyl
pyrophosphate (FPP) is catalyzed by (+)-germacrene A synthase
(GAS) to afford germacrene A. The latter is subjected to three
oxidation steps catalyzed by cytochrome P450 germacrene A
oxidase (GAO) to afford the corresponding acid. The acid is
then hydroxylated by (+)-costunolide synthase (COS) into
an unstable intermediate that undergoes a non-enzymatic
lactonization yielding costunolide (“olide” refers to lactone
group). The genetic mapping and characterization of the globe
artichoke (+)-germacrene A synthase gene, encoding the first
dedicated enzyme for biosynthesis of cynaropicrin was also
reported in this study (Menin et al., 2012; Eljounaidi et al., 2014,
2015).
The synthesis of deuterated cynaropicrin at the side chain
was achieved via esterification of hydrolyzed cynaropicrin with
deuterated side chain (Sato et al., 2015).
SOURCES OF CYNAROPICRIN
Sesquiterpene butyrolactones are natural products widely
distributed in the Asteraceae (Compositae) family of flowering
plants; cynaropicrin is a chemotaxonomic marker of artichoke
plant species (Chaturvedi, 2011) where it was isolated, among
others mentioned above, from different Cynara plants such as the
Italian and Polish C. scolymus (Samek et al., 1971; Barbetti et al.,
1993), the aerial (flowering) parts of the Japanese C. cardunculus
(Shimizu et al., 1988), lipophilic extracts of C. cardunculus L. var.
altilis (DC) (Ramos et al., 2013), and C. humilis (Reis et al., 1992).
Cynaropicrin has been also reported from the following
botanical sources: The Chinese plant Saussurea katochaete
(Asteraceae) (Saito et al., 2012), the aerial parts of Saussurea
lipshitzii collected in South Gobi (Todorova et al., 1991), the
aerial parts of Saussurea amurensis (Sham’yanov et al., 1988),
Saussurea affinis (Das et al., 1983), S. salicifolia (Dudko and
Rybalko, 1982), Saussurea costus (Pandey et al., 2007), and
Saussurea alata (Ren et al., 2007). The aerial parts of Centaurea
scoparia (Youssef and Frahm, 1994),Centaurea ptosimopappoides
(Öksüz and Serin, 1997),Centaurea bella (Daniewski andNowak,
1992), C. solstitialis (Merrill and Stevens, 1985), Centaurea
pannonica (Heuff.) (Miloševic´ Ifantis et al., 2013), the endemic
Turkish plant Centaurea hermannii (Öksüz et al., 1994), the
flowers of the endemic Turkish plantCentaurea helenioides Boiss.
(Yayli et al., 2006), Centaurea scabiosa L. (Kaminskii et al., 2011),
Centaurea phaeopappoides and C. thracica (Nowak et al., 1989),
Centaurea americana (Ohno et al., 1973), Centaurea ragusina L.
subspecies ragusina growing in Egypt (Mahmoud et al., 1986),
Centaurea canariensis (Gonzalez et al., 1978), Centaurea repens
(Stevens, 1982), Centaurea kotschyi (Oksuz and Putun, 1983),
Centaurea arguta (Gadeschi et al., 1989); the roots of the Chinese
plant Vladimiria denticulate (Jinyun et al., 2002), the aerial parts
of Leuzea rhapontica helenifolia (Nowak et al., 1988), Leuzea
carthamoides DC (Sovová et al., 2008), Acroptilon repens (Zhao
et al., 2006), Cheirolophus species (Marco et al., 1994), from three
species of Cheirolophus endemic to the Canary Islands (Gonzalez
et al., 1993), some species of subtribe Centaureinae Dumort
(Nowak et al., 1986), Volutaria abyssinica (Marzouk, 2015),
the aerial parts of three species of the genus Cousinia (Marco
et al., 1993), the aerial parts of Cousinia adenostica (Rustaiyan
et al., 1987), Aegopordon berarioides (Izaddoost et al., 1985),
Grossheimia macrocephala (Barbetti et al., 1985), Amberboa
divericata (Rojatkar et al., 1997),Amberboa ramose (Harrison and
Kulshreshtha, 1984), Amberboa tubuliflora (Ahmed et al., 1990),
Volutarella divaricata (Forgacs et al., 1981), from Chartolepis
intermedia, C. glastifolia, C. biebersteinii, and C. pterocaula,
Vernonia glutinosa (Rakotoarimanga et al., 1992), Brachylaena
species (Zdero et al., 1991), and Artemisia xerophytica (Tan et al.,
1991).
DISCUSSION AND CONCLUSIONS
Cynaropicrin has multi-medicinal potential therapeutics
evidenced not just by the ample scientific literature describing it,
but also by the plenty number of patent applications (http://www.
thegoodscentscompany.com/data/rw1701261.html, accessed 28-
2-2016). The most outstanding activity recently discovered for
cynaropicrin is the activity against HCV where it presents a very
attractive pan-genotypic anti-HCV natural product. It showed
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TABLE 1 | Overview of reported activities of cynaropicrin, its sources, models used to detect the respective effects, and applied doses.
Activity Model Dose Source of cynaropicrin References
Anti-HCV activity In vitro, using hepatic tissues infected
with different genotypes of HCV
EC50 from 0.4 to 1.4 µM for
different genotypes of HCV
Wild Egyptian artichoke leaves,
Cynara cardunculus L. var.
sylvestris (Lam.) Fiori, Compositae
(Asteraceae)
Elsebai et al., 2016b
Anti-hyperlipidemic
activity
Olive oil-loaded mice 50 and 100mg/kg, (2 h after
olive oil administration)
Artichoke leaves, Cynara
scolymus L.
Shimoda et al., 2003
Anti-tumor and
cytotoxic activity
Quantification of major adhesion
molecules (CD98 and CD29) in
macrophages, using a quantitative
aggregation assay established with
U937 cells
IC50 2.98 and 3.46 µM,
respectively
Cynaropicrin (purity: 97%) was
purified from roots of Saussurea
lappa
Cho et al., 2004a
Leukocyte cancer cells (e.g., lymphoma
or leukemia)
Cynaropicrin dose-dependently
decreased the viability of U937,
Eol-1 and Jurkat T cells with
IC50 values of 3.11, 10.9 and
2.36 µM, respectively
Roots of Saussurea lappa Cho et al., 2004b
Human gastric adenocarcinoma (AGS)
cells
IC50 0.68 µg/ml The aerial part of the Mongolian
medicinal plant Saussurea salicifolia
Kang et al., 2007
IL-6-inducible and constitutive STAT3
activation in THP- 1 cells and the cell line
DU145
IC50 of 12 µM Cynaropicrin was purchased from
PhytoLab (Vestenbergsgreuth,
Germany)
Butturini et al., 2013.
Homozygotization Index (HI) test on two
diploid strains of Aspergillus nidulans:
UT184//UT448
Cells exposed to the drug at a
concentration of 25 µg/ml
From Moquinia kingii (H. Robinson)
Gamerro (Vernonieae, Compositae)
Salvador et al., 2008
Solid and ascites tumors (S-180
sarcoma and Ehrlich carcinoma)
IC50 values of 2.5 and 2.4 µg/ml
for cynaropicrin
Isolated from the Tibetan plant
Saussurea eopygmaea,
Compositae
Zong et al., 1994.
SK-OV-3, LOX-IMVI, A549, MCF-7,
PC-3, and HCT-15 cell lines
IC50 values between 1.1 and 8.7
µg/ml
From the flowers of Hemisteptia
lyrata Bunge
Ha et al., 2003.
Human cancer cell lines of malignant
melanoma (SK-MEL), epidermoid (KB),
ductal (BT-549) and SK-OV-3
IC50 values between 2.0 and 6.3
µg/ml
From the aerial parts of
Centaurothamnus maximus,
Compositae
Muhammad et al.,
2003.
Sulforhodamin B Bioassay (SRB) against
five cultured human tumor cells: A549,
SK-OV-3, SK-MEL-2, XF498 (CNS), and
HCT-15
ED50 values ranging from 0.29
to 1.37 µg/ml
From Saussurea calcicola,
Compositae
Choi et al., 2005.
SK-MEL-2 and SK-OV-3 human tumor
cell lines
ED50 values of 4.07 µM, and
7.42 µM, respectively
From the aerial parts of Saussurea
pulchella, Compositae
Yang et al., 2008
Human leukemia cell lines HL-60 and
U937
IC50 values of 2.0 ± 0.9 and
5.1 ± 0.4 µM/L
From the aerial parts of Centaurea
omphalotricha, Compositae
Kolli et al., 2012
Anti-inflammatory
activity
Murine macrophage RAW264.7 cells,
and U937 cells
IC50 on TNF-α production was
2.86 µg/ml
Roots of Saussurea lappa Cho et al., 1998
The release of TNF-α and NO from either
differentiated U937 cells or RAW264.7
cells activated by lipopolysaccharide and
interferon-γ
IC50s between 1.1 and 8.24 µM Roots of Saussurea lappa Cho et al., 2000
Antiphotoaging and
antioxidant activities
Melanocytes The cells were pretreated with
cynaropicrin 2, 4 or 8 µM
Artichoke (Cynara scolymus) Tanaka et al., 2013
Keratinocytes EC50 and CC50 on Nqo1
induction was 0.89 and 47.6
µM, respectively
Artichoke (Cynara scolymus)
PenCDF-induced toxicity in mice 20 mg/kg Artichoke (Cynara scolymus) Yamada et al., 2015
Antibacterial activity The MurA enzymes of E. coli K12 and
P. aeruginosa PAO1293
IC50 = 12.5 µM for E. coli MurA,
at 12 nM. IC50 = 12.1 µM for P.
aeruginosa MurA, at 150 nM
Leaves of Cynara scolymus L.
(Caelo, Hilden, Germany)
Bachelier et al., 2006
(Continued)
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TABLE 1 | Continued
Activity Model Dose Source of cynaropicrin References
Anti-parasitic activity Murine model of trypanosomiasis Inhibition against T. b.
rhodesiense and T. b. gambiense
with IC50 values of 0.3 and 0.2
µM, respectively
From the herb Centaurea
salmantica L., Compositae
Zimmermann et al.,
2012; da Silva et al.,
2013
Blood collected from Trypanosoma
cruzi-infected mice
IC50 value of 93.5 µg/ml From the Brazilian plant Moquinia
kingii, Compositae
Schinor et al., 2004
Trypanosoma brucei rhodesiense,
T. cruzi, Leishmania donovani, and
Plasmodium falciparum in rat myoblast
cells (L6-cells) as in Mokoka et al., 2011
IC50 values of 0.23, 5.14, 1.56,
and 1.56 µM, respectively
From Vernonia mespilifolia,
Compositae
Mokoka et al., 2013
Opisthorchosis model in golden
hamsters
At a dose of 0.8 mg/kg, the
samples taken from hamsters
treated with cynaropicrin showed
no fluke eggs under the
microscope on the 7th day
The aerial parts from Saussurea
salsa (Pall.) Spreng.
Drab et al., 2005
Antifeedant activity 4th instar larvae of Bihar hairy caterpillar,
Diacrisia obliqua Walker and the Erisilk
worm Philosamia ricini Hutton
The compound was tested at
0.02, 0.05, 0.25, 0.5 and 1%
cynaropicrin in acetone. EC50
0.01 and 0.41, respectively
From Centaurea ptosimopappa
Hayek and Trichlorepis glaberrima
DC, Compositae
Bhattacharyya et al.,
1995
Three species of stored product insect
pests; Sitophilus granarius beetles,
Tribolium confusum larvae and
Trogoderma granarium larvae
Average index value activity of
66.6
From aerial parts of Rhaponticum
pulchrum
Cis et al., 2006
Gastric actions Male Sprague-Dawley strain SPF rats
(Nippon SLC, Shizuoka, Japan)
Cynaropicrin at an oral dose of 5
mg/kg markedly prevented the
mucosal injury by 98%
Artichoke (Cynara Scolymus L.) leaf
extract
Ishida et al., 2010)
Male Sprague-Dawley rats At low doses, cynaropicrin is one
of the main active choleretic
principles in S. amara
Aerial parts of Saussurea amara,
Compositae
Glasl et al., 2007
Guinea-Pig ileum IC50 value of 0.065 mg/ml From Brazilian Cynara scolymus Emendörfer et al.,
2005
potent and broad spectrum potential against the major genotypes
of HCV by inhibiting viral cell entry.
The discovery of novel anti-HCV entry inhibitors
such as cynaropicrin could help to develop preventive
therapies/measures against hepatitis C where immunization
against HCV is at present unavailable due to the highly mutable
nature of the virus. Important applications of entry inhibitors
include the prevention of recurrence in the new liver in HCV-
patients after liver transplantation. In patients with HCV-related
end-stage liver diseases undergoing liver transplantation, re-
infection of the graft is universal and characterized by accelerated
progression of liver diseases. Entry inhibitors may be effective
especially in these patients undergoing violent re-infection of
HCV into hepatocytes (Nakajima et al., 2013).
From the histo-pharmacology of cynaropicrin action, it seems
that most of its pharmacological effects are convergent to support
the anti-HCV activity, as follows:
(1) Cynaropicrin was found to suppress hyperlipidaemia as
mentioned above (Shimoda et al., 2003). The lipids are important
factors for the life-cycle of HCV where the virus replication
and assembly is dependent on host cell lipid metabolism. HCV
attaches itself to lipids and very-low-density lipoproteins after its
release from the infected cells. It will then circulate in the blood in
the form of triglyceride-rich particles (Burlone and Budkowska,
2009). It was also demonstrated that HCV-core protein (C), and
the non-structural proteins NS2 and NS5A of HCV induce lipid
accumulation in the liver cells resulting in steatosis, fatty liver
and potential progression of liver disease and associated with
hepatic inflammation and fibrosis. Therefore, it is important to
lower increased cholesterol and triglycerides concentrations in
HCV-infected patients (Kim et al., 2009).
(2) Cynaropicrin is a potent antioxidant (Takei et al., 2015;
Yamada et al., 2015) and hence it can play a supportive role
for liver in different hepatic diseases. Oxidative stress plays
an important role in the pathogenesis of chronic hepatitis C.
Oxidative stress occurs early during HCV infection and increases
with disease progression and severity and hence the infected
patient with HCV is usually being advised to take antioxidants
such as vitamins C, D, and E, which are the most investigated
as antioxidant therapy in chronic liver diseases (Milliman et al.,
2000).
(3) Cynaropicrin is a potent inhibitor of TNF-α action which
is a major mediator of the inflammatory process in HCV patients.
Serum levels of TNF-α have been correlated with elevated alanine
aminotransferase (ALT) and increased severity of fibrosis in HCV
patients. Patients receiving interferon showed decreased TNF-α
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FIGURE 5 | Proposed biosynthetic pathway for cynaropicrin.
concentration (Milliman et al., 2000). It is also suggested that
the activation of the NF-κB and AKT pathways are involved in
increased HCV replication (Brenndörfer et al., 2009).
(4) Since cancer is the result of a deregulation of multiple
signaling pathways and cynaropicrin elicit multi-targeted
activities, this natural product could hold a great potential
for treating human tumors. Cynaropicrin having significant
antitumor activity and it may be served as potential cancer
chemopreventive lead drug for prevention or treatment of
human cancers (Kang et al., 2007). Human infection with
HCV is currently recognized as the leading cause of the severe
complications such as HCC which demands liver transplantation
(Ishida et al., 2014) since HCC is the major histological subtype
of primary liver cancer (Hu et al., 2013). A total of ∼27% of
individuals that develop liver cirrhosis and HCC worldwide arise
in HCV-infected people (Ishida et al., 2014). It appears to be
the major causative factor responsible for the recent doubling
of HCC which was estimated to result in ∼10,000 deaths in
the United States only in the year 2011 (Gonzalez et al., 2009;
Ibrahim et al., 2013). Cynaropicrin has anti-inflammatory,
anti-tumor, TNF-α inhibitory, and antioxidant activities and
hence it can also prevent the progression of HCC. Indeed, most
natural agents do not induce a high level of toxicity and target
multiple signaling pathways involved in cell growth, invasion,
apoptosis, angiogenesis and metastasis (Pulito et al., 2015).
Cynaropicrin as a potential therapeutic compound is having
many other advantages:
(1) The cynaropicrin is one of the main active constituents
of artichoke; the therapeutic effects of the latter have been
observed in several clinical trials (Giacosa et al., 2015) and it
has recently attracted attention because of its well-proven safety
at concentrations currently employed in alcoholic beverages
(Cravotto et al., 2005). Another clinical study recommended
artichoke extract for treating hyperlipoproteinemia and, thus,
prevention of atherosclerosis and coronary heart disease and
showed that there were no drug-related adverse events indicating
an excellent tolerability of artichoke extract (Englisch et al., 2000).
Artichoke is a fundamental component of Mediterranean diet
and is available globally in all markets (Pulito et al., 2015). (2)
The compound is water-soluble and hence therapeutic injections
can be formulated which will decrease the amount of dosage form
and shorten the duration of therapy and thus reducing putative
side effects.
(3) The compound has a simple structure and hence it can be
synthesized and marketed with affordable prices.
The final conclusion is that cynaropicrin is a very effective
and promising natural product for hepatitis C virus infection
and a prospective new drug lead, since it has a direct action on
HCV by cell entry inhibition and cell-cell coinfection inhibition
and also it may exert inhibitory effects on HCV replication
via suppression of one or more signaling pathways related to
ROS, Akt, NF-κB, and STAT3. Further in-depth studies including
clinical trials are needed to fully evaluate its value for HCV
treatment. Thus, cynaropicrin represents a natural product with
an excellent therapeutic potential that can be considered as one
illustrative example in line with the re-emerging notion that
medicinal plants are expected to be a continues magnificent
source of molecules with therapeutic potential (Atanasov et al.,
2015).
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